Global Nuclear Medicine Radioisotopes Market Report and Forecast 2024-2032

Global Nuclear Medicine Radioisotopes Market Report and Forecast 2024-2032


Global Nuclear Medicine Radioisotopes Market Report and Forecast 2024-2032

Global Nuclear Medicine Radioisotopes Market Outlook

The global nuclear medicine radioisotopes market size was valued at USD 8.9 billion in 2023, driven by a continuous push for advancements in imaging technology across the globe. The market size is anticipated to grow at a CAGR of 8% during the forecast period of 2024-2032 to achieve a value of USD 17.9 billion by 2032.

Nuclear Medicine Radioisotopes: Introduction

Nuclear medicine radioisotopes are radioactive compounds used in medical imaging and therapy. In diagnostic imaging, they emit gamma rays detectable by special cameras, providing detailed images of the body's internal structure and function. In therapy, radioisotopes target and destroy abnormal cells, like in cancer treatment. These isotopes are crucial for diagnosing conditions, monitoring treatment progress, and delivering targeted therapies, offering a unique blend of diagnostic and therapeutic capabilities in various medical specialties.

Key Trends in the Global Nuclear Medicine Radioisotopes Market

There's a continuous push for advancements in PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and theranostics, providing clearer, more detailed images and enabling more precise and targeted treatments.

The field of theranostics (therapy combined with diagnostics) is rapidly growing, with radioisotopes playing a pivotal role in both imaging and treating diseases, particularly in oncology.

There's an increasing trend towards personalized medicine, where treatments are tailored to individual patients. Radioisotopes in nuclear medicine are integral to this approach, offering personalized diagnostic and treatment options based on specific patient profiles.

Innovations in the production of radioisotopes, including the development of cyclotrons and nuclear reactors dedicated to medical isotope production, are addressing previous supply issues and ensuring a more stable supply chain.

Changes in the regulatory and reimbursement landscape are influencing the market. There's a push towards establishing clear guidelines and reimbursement policies to support the adoption of nuclear medicine therapies.

With the growing use of radioisotopes in medical applications, there's an increased focus on safety and quality control throughout the lifecycle of these products, from production to patient administration.

Collaborations between pharmaceutical companies, medical device manufacturers, and research institutions are fostering innovation and speeding up the development and commercialization of new radioisotope products.

While established markets continue to grow, emerging markets are increasingly adopting nuclear medicine practices, driven by improving healthcare infrastructures and increasing awareness of advanced diagnostic and therapeutic techniques.

Global Nuclear Medicine Radioisotopes Market Segmentation

Market Breakup by Radioisotope Type
  • Technetium-99m (Tc-99m)
  • Thallium-201 (Tl-201)
  • Iodine (I-123)
  • Fluorine-18, Rubidium-82 (Rb-82)
  • Iodine-131 (I-131)
  • Lutetium-177 (Lu-177)
  • Radium-223 (Ra-223)
  • Alpharadin
  • Actinium-225 (Ac-225)
  • Others
Market Breakup by Application
  • Oncology
  • Cardiology
  • Thyroid
  • Neurology
  • Other Applications
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Nuclear Medicine Radioisotopes Market Overview

In North America, the nuclear medicine radioisotopes market is highly developed, driven by advanced healthcare infrastructure, substantial investment in research and development, and a high prevalence of cancer and cardiovascular diseases. The region leads in the adoption of innovative diagnostic and therapeutic radioisotopes, supported by strong regulatory frameworks and a focus on precision medicine. Collaborations between nuclear medicine companies, research institutions, and hospitals contribute to the dynamic growth and application of radioisotopes in clinical settings.

Europe's market benefits from a well-established healthcare system, significant research funding, and collaborative networks across countries. The region emphasizes high-quality standards in nuclear medicine, with a strong focus on safety, efficacy, and ethical considerations. European policies support the development of advanced radioisotope production facilities and encourage innovation in radioisotope therapy and imaging. The market is also shaped by initiatives aimed at ensuring a stable supply of medical radioisotopes and promoting their clinical use.

The market in the Asia-Pacific region is rapidly expanding, driven by increasing healthcare expenditure, a growing elderly population, and a rising incidence of chronic diseases. Countries like Japan, South Korea, China, and Australia are investing in nuclear medicine facilities and technologies. However, the market's growth is varied, with differences in healthcare infrastructure, regulatory landscapes, and access to nuclear medicine services across countries. Efforts to improve healthcare services, coupled with increasing regional collaboration, are key factors fueling the market's growth.

Global Nuclear Medicine Radioisotopes Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • GE HealthCare
  • Cardinal Health
  • Curium
  • Bayer AG
  • Lantheus Holdings, Inc.
  • Bracco Imaging S.p.A.
  • PharmaLogic Holdings Corp.
  • Eczacibasi-Monrol Nuclear Products
  • Nordion Inc.
  • NorthStar Medical Radioisotopes
  • NTP Radioisotopes SOC Ltd
  • Aenorasis
  • Positron Corporation
  • Nordion Inc. (Sotera Health Company)
  • Siemens Healthineers
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Nuclear Medicine Radioisotopes Market Overview
3.1 Global Nuclear Medicine Radioisotopes Market Historical Value (2017-2023)
3.2 Global Nuclear Medicine Radioisotopes Market Forecast Value (2024-20312)
4 Global Nuclear Medicine Radioisotopes Market Landscape
4.1 Global Nuclear Medicine Radioisotopes Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Nuclear Medicine Radioisotopes Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Nuclear Medicine Radioisotopes Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis`
6 Global Nuclear Medicine Radioisotopes Market Segmentation
6.1 Global Nuclear Medicine Radioisotopes Market by Radioisotope Type
6.1.1 Market Overview
6.1.2 Technetium-99m (Tc-99m)
6.1.3 Thallium-201 (Tl-201)
6.1.4 Iodine (I-123)
6.1.5 Fluorine-18, Rubidium-82 (Rb-82)
6.1.6 Iodine-131 (I-131)
6.1.7 Lutetium-177 (Lu-177)
6.1.8 Radium-223 (Ra-223)
6.1.9 Alpharadin
6.1.10 Actinium-225 (Ac-225)
6.1.11 Others
6.2 Global Nuclear Medicine Radioisotopes Market by Application
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiology
6.2.4 Thyroid
6.2.5 Neurology
6.2.6 Other Applications
6.3 Global Nuclear Medicine Radioisotopes Market by End User
6.3.1 Market Overview
6.3.2 Hospital
6.3.3 Diagnostic labs
6.3.4 Others
6.4 Global Nuclear Medicine Radioisotopes Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Nuclear Medicine Radioisotopes Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Nuclear Medicine Radioisotopes Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Nuclear Medicine Radioisotopes Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Nuclear Medicine Radioisotopes Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Nuclear Medicine Radioisotopes Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 GE HealthCare
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Cardinal Health
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Curium
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Bayer AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Lantheus Holdings, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Bracco Imaging S.p.A.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 PharmaLogic Holdings Corp.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Eczacibasi-Monrol Nuclear Products
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Nordion Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 NorthStar Medical Radioisotopes
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 NTP Radioisotopes SOC Ltd
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Aenorasis
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Positron Corporation
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Nordion Inc. (Sotera Health Company)
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 Siemens Healthineers
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Nuclear Medicine Radioisotopes Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings